文献速递乳腺癌

加速部分乳腺照射采用调强放疗对比全乳照射:佛罗伦萨3期试验的健康相关生活质量最终分析

Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: Health-related quality of life final analysis from the Florence phase 3 trial.
PubMed 文献 · Eur J Cancer · 2017-03-03

该3期随机试验纳入520例早期乳腺癌保乳术后患者,205例完成生活质量问卷分析,比较APBI-IMRT与全乳照射。结果显示APBI组在治疗结束时和2年随访时多项生活质量量表显著优于全乳照射组,作者认为对选定低危患者应强烈考虑APBI。

要点

  • APBI组在治疗结束时总体健康状况及多数功能、症状量表显著优于全乳照射组。
  • 2年随访时APBI组总体健康状况、体像感知、未来展望及乳腺和手臂症状仍显著更优。
  • 作者建议对选定的低危早期乳腺癌患者强烈考虑APBI,但需等待成熟局部控制结果。

核心结论

  • 早期乳腺癌接受APBI较全乳照射在短期及2年随访显示更好的健康相关生活质量结局。
  • 作者认为对选定的低危患者应强烈考虑APBI。
  • 正在进行的充分把握度随机试验的成熟局部控制结果有待报告。

研究设计与样本

  • APBI-IMRT-Florence 3期随机试验(NCT02104895),共入组520例患者。
  • 纳入标准为年龄超过40岁、适合保乳手术的早期乳腺癌女性。
  • APBI方案为30 Gy分5次,采用IMRT技术。
  • 全乳照射方案为50 Gy分25次,加肿瘤床推量10 Gy分5次。
  • 本分析纳入205例完整完成所有问卷的患者(APBI组105例,全乳照射组100例)。

主要发现

  • T0时两组QLQ-C30和BR23评分无显著差异。
  • T1时总体健康状况(p=0.0001)及QLQ-C30多数功能和症状量表评分显示显著差异,有利于APBI组。
  • T1时BR23功能与症状量表中,体像感知、未来展望及乳腺和手臂症状在APBI组显著更好。
  • T2时总体健康状况(p=0.0001)及QLQ-C30多数功能和症状量表显示显著差异,有利于APBI组。
  • T2时BR23功能量表中体像感知和未来展望在APBI组显著更好(p=0.0001),症状量表中乳腺和手臂症状在APBI组显著更好(p<0.01)。

临床怎么用

  • 作者认为对选定的低危早期乳腺癌患者,在治疗选择中应强烈考虑APBI。
  • 作者指出正在进行的充分把握度随机试验的成熟局部控制结果有待报告。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Accelerated partial breast irradiation (APBI) represents a valid option for selected early breast cancer (BC). We recently published the 5-year results of the APBI-IMRT-Florence phase 3 randomised trial (NCT02104895), showing a very low rate of disease failure, with acute and early-late toxicity in favour of APBI. We present the early and 2-year follow-up health-related quality of life (HRQoL) results. METHODS: Eligible patients were women aged more than 40 years with early BC suitable for breast-conserving surgery. APBI consisted of 30 Gy in five fractions delivered with IMRT technique. Standard whole breast irradiation (WBI) consisted of 50 Gy in 25 fractions plus a 10 Gy in five fractions boost on tumour bed. A total of 520 patients were enrolled in the phase 3 trial. Overall, 205 patients (105 APBI and 100 WBI) fully completed all the given questionnaires and were therefore included in the present analysis. As HRQoL assessment, patients were asked to complete the European Organisation for Research and Treatment of Cancer QLQ-C30, and the BR23 questionnaires at the beginning (T0), at the end (T1) and after 2 years from radiation (T2). FINDINGS: No significant difference between the two arms at QLQ-C30 and BR23 scores emerged at T0. Global health status (p = 0.0001), and most scores of the functional and symptom scales of QLQ-C30 at T1 showed significant differences in favour of the APBI arm. Concerning the BR23 functional and symptom scales, the body image perception, future perspective and breast and arm symptoms were significantly better in the APBI group. Similar significant results emerged at T2: significant differences in favour of APBI emerged for GHS (p = 0.0001), and most functional and symptom QLQ-C30 scales. According to QLQ-BR23 module, among the functional scales, the body image perception and the future perspective were significantly better in the APBI group (p = 0.0001), whereas among the symptom scales significant difference emerged by breast and arm symptoms with better outcomes in APBI arm (p < 0.01). INTERPRETATION: Early BC treated with APBI showed an improved short-term, and 2-year follow-up HRQoL outcome as compared with WBI. Early BC treated with APBI showed an improved short-term, and 2-year follow-up HRQoL outcome as compared with WBI. APBI should be strongly considered in the treatment choice for selected low-risk patients. Mature local control results from ongoing adequately powered randomised trials are awaited.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Meattini I, Saieva C, Miccinesi G, et al. Accelerated partial breast irradiation using intensity modulated radiotherapy versus whole breast irradiation: Health-related quality of life final analysis from the Florence phase 3 trial. Eur J Cancer. 2017. PMID: 28262584. doi:10.1016/j.ejca.2017.01.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。